- Pluristem Therapeutics (NASDAQ:PSTI) collaborates with NASA’s Ames Research Center to evaluate the potential of Pluristem’s PLX cell therapies in preventing and treating medical conditions caused during space missions.
- The project, titled, “Therapeutic Stromal Cells for Health in Space,” has been selected to prevent and treat medical conditions relating to blood, bone, muscle, brain and heart.
- Shares are up 5% premarket.